Michael Ison
Infectious Disease · Falls Church, VANPI 1316941222
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $72,848 of the $87,958 with a category attached, or 82.8%. It is spread thinly across 14 manufacturers, the largest accounting for just 16.8%. Reporting peaked in 2022 at $34,403 and has fallen 100.0% since, to $14 in 2025. Among infectious disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $1441.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$15K
- Merck$14K
- ADMA Biomanufacturing LLC$13K
- GSK$11K
- Shionogi Inc$9K
- Janssen Global Services, LLC$7K
- plus $19K from 8 others
Across 39 payments — averaging $6323.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$94K
- Shire North American Group Inc$38K
- Astellas Pharma Global Development$33K
- Cepheid$28K
- Roche Products Limited$21K
- GSK$15K
- plus $16K from 6 others
What the payments were for
- Consulting fees$72,84883%
- Speaking & faculty fees$3,2914%
- Travel & lodging$11,53113%
- Food & beverage$2890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 6 | $14,784 |
| Merck | 18 | $14,275 |
| ADMA Biomanufacturing LLC | 3 | $13,000 |
| GSK | 6 | $10,533 |
| Shionogi Inc | 7 | $9,097 |
| Janssen Global Services, LLC | 6 | $7,106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $3,735 |
| Sanofi-aventis U.S. LLC | 2 | $3,515 |
| CSL Behring | 4 | $3,150 |
| Roche Diagnostics Corporation | 1 | $2,900 |
| Celltrion, Inc. | 1 | $2,400 |
| Genentech, Inc. | 2 | $2,400 |
| Seqirus USA Inc | 1 | $1,050 |
| Kerecis Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$12,684
- PREVYMIS$9,750
- Fetroja$7,220
- Xofluza$3,300
- MD cobas Instruments and Reagents$2,900
- NO PRODUCT DISCUSSED$2,237
How this compares
$87,958 in reported general payments places this provider in the 95th percentile of 194 infectious disease providers in Virginia.
Other infectious disease in Falls Church
- Sajal TannaFalls Church$2K
- Prachi RanadeFalls Church$696
- Christopher BettacchiMarion$243K
- Stephen WeinrothFairfax$157K
- William PetriCharlottesville$92K
- Valerie RiddleBumpass$83K
- Edward OldfieldNorfolk$81K
- William FurlongArlington$68K
- Frederick HaydenCharlottesville$61K
- David WheelerAnnandale$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.